CD19 and systemic lupus erythematosus: The FDA's approval of inebilizumab for neuromyelitis optica spectrum disorder (NMOSD), coupled with promising results from studies using CD19-targeting CAR T-cells in SLE and refractory antisynthetase syndrome, supports this strategy [94].